Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ
* Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year * Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year * Net Profit Attributable to the Owners of the Com...
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time
* Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up 25.6% * Net Profit Attributable to the Owners of the Company[1] Increased 9.0% to RMB9,607 Million; Diluted Earnings per Share (EPS) Increased 14.9% to RMB3.24 * Adjusted Non-IFRS Net Profit Att...
WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022
* Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 39.5% * Revenue of RMB18,871 Million in the First Half, Up 6.3% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 27.9% * Net Profit Attributable to Owners of the Co...
WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022
Revenue Up 5.8% Year-Over-Year to RMB8,964 Million Net Profit Attributable to Owners of the Company Up 32.0% Year-Over-Year to RMB2,168 Million Diluted Earnings per Share (EPS) Up 35.8% Year-Over-Year to RMB0.72 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 14.1% Year-Over-...
WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index
SHANGHAI, Dec. 20, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, today announced that it has been included in the 2022 Dow Jones Sustainability™ World Index (DJSI). This demonstrates th...
WuXi AppTec Receives 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan
SHANGHAI, Nov. 29, 2022 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced that it is a r...
WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion
Revenue Up 71.9% Year-Over-Year to RMB28,395 Million Net Profit Attributable to Owners of the Company Up 107.1% Year-Over-Year to RMB7,378 Million Diluted Earnings Per Share (EPS) Up 90.1% Year-Over-Year to RMB2.30 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 77.9% Year...
WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility
New facility expands integrated drug product R&D and manufacturing services to global customers SHANGHAI, Sept. 26, 2022 /PRNewswire/ -- WuXi STA, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of its first high potency (HP) o...
WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers
SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection dosag...
WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware
MIDDLETOWN, Del., Aug. 16, 2022 /PRNewswire/ -- WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus inMiddletown, Delaware. First announced in June 2021, this...
WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology
PHILADELPHIA, Aug. 11, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen"). Under this agreement, WuXi ATU ...
WuXi AppTec Plans to Build a New Site in Singapore, Better Serving Global Partners and Advancing Healthcare Innovation
SINGAPORE, July 19, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, today announced a plan to build a new R&D and manufacturing site inSingapore. The company intends to invest up to S$2 bi...
WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility
Site Enhances New Modality CRDMO Platform Capacity for Customers SHANGHAI , July 6, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at itsChangzhou campus. The new facility underscores...
WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies
PHILADELPHIA and ST. LOUIS, MO and SAN DIEGO, June 15, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based inSt. Louis and San Diego, today announced a ...
WuXi AppTec Reports Record First-Quarter In 2022
Revenue Up 71.2% Year-Over-Year to RMB8,474 Million Net Profit Attributable to Owners of the Company Up 9.5% Year-Over-Year to RMB1,643 Million Diluted Earnings Per Share (EPS) Up 3.9% Year-Over-Year to RMB0.53 Adjusted Non-IFRS[1] Net Profit Attributable to Owners of the Company Up 85.8% Ye...
WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies
PHILADELPHIA, March 7, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manu...
